Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

AstraZeneca (AZN) is highlighted as a compelling long-term value stock, despite its Zacks Rank #3 (Hold), due to its strong VGM Score of A and Value Style Score of B, underpinned by an attractive forward P/E of 17.83. The company has seen positive analyst revisions, with six analysts raising fiscal 2025 earnings estimates, pushing the Zacks Consensus Estimate up by $0.09 to $4.58 per share, alongside a consistent +3.5% average earnings surprise. These metrics, particularly the strong Style Scores and upward earnings forecast, position AZN as a noteworthy consideration for value-oriented investors.

Analysis

AstraZeneca (AZN) is presented as a compelling case for value investors, despite its neutral Zacks #3 (Hold) rank. The stock's profile is supported by strong underlying metrics, including a top-tier composite VGM Score of 'A' and a 'B' grade for Value. This value proposition is quantified by an attractive forward P/E ratio of 17.83. More significantly, the forward-looking earnings outlook appears to be improving, as evidenced by six upward analyst revisions for fiscal 2025 within the last 60 days. This has lifted the consensus earnings per share estimate by $0.09 to $4.58 for that period. The company also demonstrates a consistent ability to exceed expectations, boasting an average positive earnings surprise of 3.5%. The combination of a neutral short-term rank with strong value scores and positive earnings estimate momentum suggests that while the stock may lack immediate catalysts for a breakout, its fundamental valuation and improving long-term outlook are noteworthy.

Key Decisions for Investors

• Value-oriented investors may find the stock's 'B' Value Score and forward P/E of 17.83 to be an attractive entry point for a large-cap biopharmaceutical company.
• Given the neutral #3 (Hold) rank, it is prudent to weigh the lack of short-term momentum against the positive fundamental signals, such as the consistent +3.5% average earnings surprise and the 'A' VGM score.
• Investors should closely monitor future earnings estimate revisions for fiscal 2025, as continued upward adjustments could serve as a leading indicator for a potential rank upgrade and subsequent share price appreciation.